Globus Medical Inc Stock News

Globus Medical (NYSE:GMED) is scheduled to announce Q4 earnings results on Thursday, Feb. 17, after market close.The consensus EPS estimate is $0.47 (-19% Y/Y)

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.

Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors

AUDUBON, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full yea

AUDUBON, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

UBS is maintaining its buy rating on Globus Medical citing a survey of spine and neurosurgeons indicating it is poised to gain the most market share among competitors.

Encompass Health (EHC) expects the Enhabit Home Health & Hospice spinoff to be completed in first-half 2022.

Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.

Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.

Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day